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HYPERCHOLESTEROLEMIA. an important risk factor for the development of serious premature 
cardiovascular disease. has been observed in renal trans-
plant patients. 1•2 Its pathogenesis has been thought to be 
related to corticosteroid therapy.2 However. it appears 
that FK 506. a new and highly potent immunosuppressant. 
on the other hand can inhibit the development oftransplant 
arteriosclerosis. 3 Furthermore, in a recent study by one of 
us (R.S.) comparing FK 506 with cyclosporine in renal 
transplant patients: a significantly higher serum choles-
terol level was seen in patients receiving cyclosporine 
compared with patients receiving FK 506. To study this 
problem further, we looked at serum cholesterol levels in 
37 adult African Americans who received renal transplant 
allografts under FK 506 at the University of Pittsburgh 
Medical Center between October 26. 1989 and July 24. 
1m. 
PATIENTS AND METHODS 
Thirty-seven adult African Americans who received renal trans-
plant allografts only and were immunosuppressed primarily with 
FK 506 were retrospectively analysed. 
All patients received FK S06 and prednisone. In 18 patients. 
however. azathioprine was also added. There were 23 males and 
14 females. All patients had a minimum postoperative foUow-up of 
4 weeKs. Serum cholesterol levels were obtained during the 
preoperative evaluation and monitored postoperaively. Patients 
were classified as diabetic 'or nondiabetic as defined by Scande-
bury et al. 5 Statistical analysis for observed differences was done 
using the Mann-Whitney U test. Differences of P < .OS were 
conSidered significant. 
RESULTS 
Fifty-seven percent (21137) of patients were under the age 
of 40 years. Twenty-two percent (8137) were undergoing 
retransplantation. Thirty-eight percent (14137) were insu-
lin-dependent diabetics while 62% (23137) were nondiabet-
ics. 
As a group. over the 3-month period. the serum choles-
terol level rose from a median of 174.0 mg/dL (range 88.0 
to 278.0 mgldL) in the first week to 194.0 mgldL (range 102 
to 325.0 mg/dU in the first month and then pealced at 211.0 
mgldL (range 134.0 to 315.0 mg/dLl in the second month 
(P = .824). However. by the end of the third month. it had 
dropped to to 198.0 mgldL (range 128.0 to 356.0 mgldU. 
When the group was subdivided into diabetics and non-
diabetics. this trend was seen in the diabetics but not in the 
nondiabetics. In the nondiabetics. the level rose from a 
median of 163.0 mgldL (range 88.0 to 278.0 mg/dL) in the 
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first week to 179.0 mgldL (range 102.0 to 291.0 mgldL) in 
the first month and then plateaued at 190.5 mgldL (range 
134.0 to 279.0 mgldL) in the second (P = .552) and 191.0 
mg/dL (range 128.0 to 356.0 mg/dL) in the third month 
(P = .178). 
Although there was some dift'erence in the cholesterol 
levels over time, they were not statistically different. 
DISCUSSION 
While no discernable pattern was seen in serum choles-
terollevels after transplantation. it is important to note that 
they were basically normal. at least in the early posttrans-
plant period. There is abundant epidemiologic and clinical 
data that implicate hypercholesterolemia as an important 
risk factor in the occurence of myocardial infarction at a 
young age."'? Therefore, the occurence ofhypercholester-
olemia in transplant patients can pose a long-term prob-
lem. Cardiovascular complications account for about 40% 
of deaths that occur within 3 months of transplantation. 8 
Reports that FK 506 can inhibit posttransplant arterioscle-
rosisJ and be associated with a signficant lowering of 
serum cholesterol when compared with cyclosporine,4 
may have important long-term implications. if these find-
ings translate into lowered cardiovascular risks. 
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